
Bacitracin
CAS No. 1405-87-4
Bacitracin( Bacitracin )
Catalog No. M11703 CAS No. 1405-87-4
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 27 | In Stock |
![]() ![]() |
100MG | 38 | In Stock |
![]() ![]() |
200MG | 52 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameBacitracin
-
NoteResearch use only, not for human use.
-
Brief DescriptionBacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy.
-
DescriptionBacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy, which disrupts both gram positive and gram negative bacteria by interfering with cell wall and peptidoglycan synthesis.(In Vitro):Bacitracin (64 μg/mL, 24 h) together with Colistin shows antibacterial activity against S. aureus BA01611.Bacitracin (64 μg/mL, 1 or 2 h) damages the cell surface to grape-like cell clusters, and the cell boundaries are faint and unclear.(In Vivo):Bacitracin (0-100 mg/kg, intramuscular injection, daily for 12 consecutive days) shows anti-tumor efficacy in HCC model.
-
In Vitro——
-
In VivoAnimal Model:HCC model (MH134 cells implanted)Dosage:0, 10, 50, and 100 mg/kg Administration:Intramuscular injection (i.m), daily for 12 consecutive days.Result:Decreased tumor volumes. Decreased the percentage of PDI-stained vascular densities.
-
SynonymsBacitracin
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number1405-87-4
-
Formula Weight1422.73
-
Molecular FormulaC66H103N17O16S
-
Purity>98% (HPLC)
-
SolubilityWater: 100 mg/mL (70.98 mM); DMSO: 100 mg/mL (70.98 mM)
-
SMILESO=C(O)CC[C@@H](NC([C@@H](NC([C@H]1N=C([C@@H](N)[C@@H](C)CC)SC1)=O)CC(C)C)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]2C(N[C@H](CCCN)C(N[C@@H]([C@H](CC)C)C(N[C@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CN=CN4)C(N[C@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(NCCCC2)=O)=O)=O)=O)=O)=O)=O)=O)=O
-
Chemical Name(4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Toscano WA Jr, et al. Pharmacol Ther, 1982, 16(2), 199-210.
molnova catalog



related products
-
2-Hydroxy-3-(hydroxy...
2-Hydroxy-3-(hydroxymethyl)anthraquinone exhibits quinone reductase (QR)- inducing activity in Hepa lclc7 cells, with the concentration required to double QR activity of 0.94 microM.
-
[Asp371]-Tyrosinase ...
Tyrosinase (369-377,YMDGTMSQV) is derived from the membrane protein tyrosinase by posttranslational conversion of the sequence YMNGTMSQV. Presentation of YMDGTMSQV in cells expressing full-length tyrosinase is TAP-(transporter associated with antigen processing) and proteosome-dependent.
-
JNK-IN-7
JNK-IN-7 is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM). It can also inhibit phosphorylation of c-Jun, which is a substrate of JNK kinase.